AVENUE THERAPEUTICS INC by Avenue Therapeutics, Inc. Analyst Price Targets

Wall Street analyst price targets and consensus rating for AVENUE THERAPEUTICS INC by Avenue Therapeutics, Inc. (ATXI).

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$56Upside to Avg. PT+14702.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Dec 11, 2023	Maxim Group	Jason McCarthy	Initiate	Buy	$56

Analyst Ratings News

PRO
Maxim Group Initiates Coverage On Avenue Therapeutics with Buy Rating, Announces Price Target of $0.75

Maxim Group analyst Jason McCarthy initiates coverage on Avenue Therapeutics (NASDAQ:ATXI) with a Buy rating and announces Price Target of $0.75.

Benzinga Newsdesk

PRO
Aegis Capital Initiates Coverage On Avenue Therapeutics with Buy Rating, Announces Price Target of $32

Aegis Capital analyst David Bouchey initiates coverage on Avenue Therapeutics (NASDAQ:ATXI) with a Buy rating and announces Price Target of $32.

Benzinga Newsdesk

HC Wainwright & Co. Maintains Buy on Avenue Therapeutics, Raises Price Target to $13

HC Wainwright & Co. maintains Avenue Therapeutics (NASDAQ:ATXI) with a Buy and raises the price target from $12 to $13.

Vick Meyer

Oppenheimer Initiates Coverage On Avenue Therapeutics with Outperform Rating, Announces $8 Price Target

Benzinga

H.C. Wainwright Initiates Coverage On Avenue Therapeutics with Buy Rating, Announces $11 Price Target

Benzinga

15 Biggest Mid-Day Gainers For Tuesday

Benzinga

AVENUE THERAPEUTICS INC by Avenue Therapeutics, Inc.

ニュース

パートナーシップ

ベンジンガ・グローバル

AVENUE THERAPEUTICS INC by Avenue Therapeutics, Inc. Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Maxim Group Initiates Coverage On Avenue Therapeutics with Buy Rating, Announces Price Target of $0.75

PRO
Aegis Capital Initiates Coverage On Avenue Therapeutics with Buy Rating, Announces Price Target of $32

HC Wainwright & Co. Maintains Buy on Avenue Therapeutics, Raises Price Target to $13

Oppenheimer Initiates Coverage On Avenue Therapeutics with Outperform Rating, Announces $8 Price Target

H.C. Wainwright Initiates Coverage On Avenue Therapeutics with Buy Rating, Announces $11 Price Target

15 Biggest Mid-Day Gainers For Tuesday

AVENUE THERAPEUTICS INC by Avenue Therapeutics, Inc.

ニュース

パートナーシップ

ベンジンガ・グローバル

AVENUE THERAPEUTICS INC by Avenue Therapeutics, Inc. Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMaxim Group Initiates Coverage On Avenue Therapeutics with Buy Rating, Announces Price Target of $0.75

PROAegis Capital Initiates Coverage On Avenue Therapeutics with Buy Rating, Announces Price Target of $32

HC Wainwright & Co. Maintains Buy on Avenue Therapeutics, Raises Price Target to $13

Oppenheimer Initiates Coverage On Avenue Therapeutics with Outperform Rating, Announces $8 Price Target

H.C. Wainwright Initiates Coverage On Avenue Therapeutics with Buy Rating, Announces $11 Price Target

15 Biggest Mid-Day Gainers For Tuesday

PRO
Maxim Group Initiates Coverage On Avenue Therapeutics with Buy Rating, Announces Price Target of $0.75

PRO
Aegis Capital Initiates Coverage On Avenue Therapeutics with Buy Rating, Announces Price Target of $32